Logo
NEXFILL Fine (1ml with Lidocaine)

NEXFILL Fine (1ml with Lidocaine)

Nexfill

Dermal filler
  • CE Marked dermal filler range with certification obtained via a European representative in Germany, indicating conformity with relevant medical device standards.
  • Manufactured using EDQM Approved hyaluronic acid raw material and multiple purification steps to achieve ultra Low impurity levels.
  • Validated by accredited laboratories for critical quality parameters such as pH, HA concentration, BDDE residuals (reported as 0 ppm within analytical limits), endotoxin content, heavy metals, injection force and osmolarity.
  • Produced under Nexus Pharma’s quality management system consistent with international standards for injectable medical and aesthetic products.
Monophasic cross-linked hyaluronic acid dermal filler for fine lines and delicate areas

Description

NEXFILL Fine (1ml with Lidocaine) is a premium CE-marked monophasic cross-linked hyaluronic acid dermal filler from Nexus Pharma, specifically designed to treat fine lines and delicate facial areas. With a concentration of 24 mg/ml hyaluronic acid and 0.3% lidocaine for patient comfort, it targets forehead lines, crow’s feet, glabellar lines, neck wrinkles, periorbital and tear trough areas, and lip contouring (including Russian lips techniques). Thanks to ultra-low impurities, high viscoelasticity and approximately 60% less BDDE cross-linking agent than typical industry fillers, Nexfill Fine delivers deep, natural hydration, subtle volume and a radiant, healthy skin glow while minimising swelling and ensuring smooth, natural-looking results.

Bnefits

  • Provides rejuvenation with soft, natural-looking correction of fine lines and early signs of ageing.
  • Creates a radiant, healthy skin glow by improving hydration and dermal support.
  • Delivers deep hydration and moisturisation through 24 mg/ml hyaluronic acid in a monophasic gel.
  • Fills and gently tightens the skin, quickly smoothing superficial wrinkles and fine lines.
  • Particularly suited for delicate areas, including crow’s feet, periorbital lines, tear troughs and lip contouring (including Russian lips).
  • Monophasic lidocaine filler with high density and ultra-low impurity levels, ensuring homogeneous, long-lasting results.
  • Uses approximately 60% less BDDE cross-linking agent than many standard fillers, helping reduce swelling and improving purity.
  • Contains 0.3% lidocaine to reduce pain during injection and enhance overall treatment comfort.
  • Easily reversible with hyaluronidase in case of overcorrection, asymmetry or other clinical need.
  • Results typically last around 6–12 months, depending on area, technique and individual patient factors.

Indications

  • Fine facial lines and early wrinkles.
  • Forehead lines and fine horizontal wrinkles.
  • Crow’s feet at the outer corners of the eyes.
  • Glabellar lines (mild to moderate frown lines) in appropriate candidates.
  • Periorbital wrinkles and lower eyelid contouring.
  • Tear trough correction for under-eye hollows in suitably assessed patients.
  • Lip contour refinement and definition, including Russian lips techniques.
  • Perioral fine lines and mild lip volume enhancement.
  • Neck wrinkles and fine necklace lines.
  • Subtle correction and revitalisation in other superficial areas where a light, low-viscosity filler is appropriate.

Composition

  • Cross-linked hyaluronic acid 24 mg/ml (24 mg per 1 ml syringe).
  • Lidocaine 0.3% (approximately 3 mg per 1 ml) for local anaesthetic effect and increased comfort.
  • BDDE (1,4-butanediol diglycidyl ether) as cross-linking agent, used at roughly 60% lower levels than many standard fillers, with residual BDDE below analytical detection limits according to manufacturer testing.
  • Physiological buffer and excipients in purified water for injection, forming a sterile, viscoelastic monophasic HA gel.
  • Each box contains one sterile 1 ml pre-filled syringe of Nexfill Fine.

Formulation

  • Monophasic, homogenous, low- to medium-viscosity cross-linked hyaluronic acid gel designed for superficial and delicate corrections.
  • 24 mg/ml HA concentration with a balance of structural support and hydrating properties suited to fine lines and periorbital regions.
  • Includes 0.3% lidocaine to minimise discomfort during injection.
  • High viscoelasticity and ultra-high density technology to support smooth extrusion and even tissue integration.
  • Intended injection depth: middle dermis for most fine lines and delicate corrections, with very careful placement in periorbital/tear trough areas by experienced injectors.
  • CE-marked injectable gel produced under stringent quality control and purification processes using EDQM-approved HA raw material.

Packaging

  • Box containing 1 x 1 ml pre-filled sterile syringe of NEXFILL Fine with Lidocaine.
  • Typically supplied with 2 x 30G 1/2" sterile single-use needles suitable for superficial and mid-dermal injection (needle specification may vary by regional pack).
  • Syringe and needles packed in a sterile blister with tamper-evident sealing.
  • Outer carton clearly labelled with product name (NEXFILL Fine), volume (1 ml), HA concentration (24 mg/ml), lidocaine content (0.3%), batch/lot number, expiry date, storage conditions, CE mark and manufacturer details (Nexus Pharma).

Usage

  • For professional use only; NEXFILL Fine must be injected by appropriately trained and licensed healthcare professionals experienced in dermal filler treatments, particularly in periorbital and lip areas.
  • Take a detailed medical history and perform a full facial assessment to confirm indications (fine lines, periorbital wrinkles, tear troughs, lip contour, etc.) and to identify contraindications; obtain informed consent.
  • Cleanse and disinfect the treatment areas thoroughly using an appropriate antiseptic solution while observing aseptic technique.
  • Attach a sterile 30G needle (or other recommended gauge) securely to the Luer lock of the pre-filled syringe; expel any visible air bubbles carefully.
  • Inject into the middle dermis for most fine lines (e.g., forehead lines, crow’s feet, glabellar lines, neck wrinkles) using techniques such as linear threading, serial puncture or fanning, with small aliquots and gentle pressure.
  • In periorbital areas and tear troughs, use extra caution: inject very slowly, with minimal product, using advanced techniques (e.g., cannula where indicated) and a thorough understanding of local anatomy; these areas should only be treated by highly experienced injectors.
  • For lip contour and subtle volume enhancement (including Russian lips techniques), inject in the vermilion border or superficial submucosal plane with small incremental amounts, regularly checking symmetry and avoiding overcorrection.
  • After injection, gently mould and smooth the treated areas if needed to ensure even distribution, avoiding excessive pressure that could displace the product.
  • Do not overfill—remember that immediate post-treatment swelling can temporarily exaggerate results; plan for potential follow-up or touch-up after swelling subsides.
  • Advise patients to avoid heavy makeup on treated areas for at least 12 hours, to minimise exposure to extreme heat or cold (sauna, sunbeds, freezing temperatures), vigorous exercise and alcohol for 24 hours, and to refrain from massaging or manipulating the treated area unless directed.
  • Instruct patients to monitor for signs of unusual pain, blanching, visual changes or other warning symptoms; these may require urgent review and, in the case of suspected vascular compromise, immediate emergency management including the use of hyaluronidase according to local protocols.
  • Do not mix NEXFILL Fine with other substances in the same syringe and do not reuse any remaining product or any syringe/needle after use.

Contraindications

  • Known hypersensitivity or allergy to hyaluronic acid, lidocaine, other amide-type local anaesthetics or any of the excipients.
  • History of severe allergic reactions or anaphylaxis.
  • Active skin or mucosal infection, inflammation, dermatitis or herpetic lesions at or near the intended injection sites.
  • Autoimmune diseases, significant immunosuppression or uncontrolled systemic illnesses where dermal filler injections may carry additional risk, unless carefully judged acceptable by the treating physician.
  • Bleeding disorders or current use of significant anticoagulant/antiplatelet therapy that may increase bruising or haematoma risk, unless appropriately managed by the clinician.
  • Pregnancy and breastfeeding, due to insufficient safety data in these populations.
  • History of keloid or hypertrophic scarring, or known granulomatous diseases, where filler injections may present increased risk of abnormal tissue response.
  • Presence of permanent or semi-permanent fillers in the planned treatment area, which may heighten complication risk unless fully assessed by an experienced injector.
  • Any other contraindications and warnings specified in the official NEXFILL Fine instructions for use or applicable dermal filler guidelines.

Adverse Effects

  • Common, usually transient injection-site reactions such as redness (erythema), swelling, tenderness, pain, warmth, itching and minor bruising.
  • Temporary papules, small lumps or irregularities at injection sites that typically resolve as the gel settles or can be gently massaged if appropriate.
  • Local haematoma or ecchymosis due to needle trauma of small vessels.
  • Short-lived numbness or altered sensation linked to lidocaine and injection trauma.
  • Occasional prolonged swelling, redness, induration or sensitivity, particularly in delicate areas, which may require clinical evaluation and symptomatic treatment.
  • Rare delayed inflammatory reactions, nodules, granulomas or hypersensitivity responses that may necessitate medical management (e.g., anti-inflammatory therapy, hyaluronidase, or other interventions).
  • As with all dermal fillers, very rare but serious complications such as intravascular injection and vascular occlusion, tissue ischaemia or necrosis, and vision changes or blindness if vessels supplying ocular structures are affected; these require immediate recognition and emergency management according to established guidelines.
  • Any persistent, unusual or severe adverse event should be promptly assessed and managed by a qualified healthcare professional and reported via appropriate device-vigilance systems.

Storage Conditions

  • Store between 2°C and 25°C (typical manufacturer range); do not freeze.
  • Keep in the original blister and outer carton to protect from light and contamination until use.
  • Do not expose to direct sunlight or excessive heat; avoid significant temperature fluctuations.
  • Do not use after the expiry date printed on the packaging.
  • Do not use if the blister pack, syringe or packaging is damaged or if sterility is in doubt.
  • Store out of reach of children and unauthorised persons; for professional use only.

Duration

Clinical and distributor information indicate that results from NEXFILL Fine typically last around 6 to 12 months, depending on the treatment area, injection depth and technique, the amount of product used, and individual factors such as age, metabolism, skin quality and lifestyle. Maintenance treatments can be scheduled within this range to sustain or adjust the aesthetic outcome.

Onset

Visible improvement in fine lines, contour and skin smoothness is usually immediate after injection, although optimal results are assessed after initial swelling and redness subside, typically within several days to two weeks. Hydration, glow and subtle textural benefits may continue to develop over the following weeks as the gel integrates and stimulates fibroblast activity.

Browse more Dermal filler

Top Treatments

Top Cities in the UK